Indian pharma major, Lupin yesterday announced that had received approval from the US health regulator, United States Food and Drug Administration (USFDA) to market its Suprax capsules, used for treating bacterial infections.
Indian pharma major, Lupin yesterday announced that had received approval from the US health regulator, United States Food and Drug Administration (USFDA) to market its Suprax capsules, used for treating bacterial infections, according to a PTI report.
Its subsidiary, Lupin Pharmaceuticals Inc, has received new drug application (NDA) approval from the United States Food and Drug Administration (USFDA) for Suprax (Cefixime) capsules in the strength of 400 mg, Lupin said in a statement. The firm is aiming at commencing shipping the product in the near future, it added.
Commenting on the development, Lupin Group President and ED Nilesh Gupta said: 'The new dosage form will add to our growing Suprax franchise and gives healthcare providers and patients a new formulation to treat the indicated infections'.The approval will expand Lupin's range of Suprax dosage forms. The product is currently available as 100 mg/5ml, 200 mg/5ml suspensions and 400 mg tablets, the statement added.
